Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5955514 | 1.00 | ACHE (0.51) | ACHERAB9APARP10PARP15PARP2 | |
| SCHEMBL30314024 | 0.90 | IRAK4 (0.56) | ACHERAB9AIRAK4GRM4 | |
| SCHEMBL14334795 | 0.90 | IRAK4 (0.56) | ACHERAB9AIRAK4GRM4 | |
| SCHEMBL14334981 | 0.90 | IRAK4 (0.49) | ACHERAB9APARP1IRAK4ROCK2 | |
| SCHEMBL14334294 | 0.86 | IRAK4 (0.60) | ACHEPARP1IRAK4ROCK2 | |
| SCHEMBL14334551 | 0.83 | IRAK4 (0.59) | PARP1IRAK4ROCK2 | |
| SCHEMBL19149183 | 0.81 | ROCK2 (0.48) | RAB9APARP10PARP15PARP1ROCK2 | |
| SCHEMBL3669098 | 0.80 | IRAK4 (0.58) | RAB9APARP1IRAK4ROCK2GRM4 | |
| SCHEMBL23462725 | 0.80 | ROCK2 (0.53) | ACHEIRAK4ROCK2 | |
| SCHEMBL14335146 | 0.80 | CYP4F2 (0.49) | ACHEIRAK4ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2023-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | ACHE 4635/4885RAB9A 2815/4885PARP10 1716/4885 |
| US-20230101484-A1 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | PDGFRB, PDGFRA, PDGFA | ACHE 4538/4885RAB9A 2531/4885PARP10 1465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.